{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-011587","form_type":"8-K","ticker":"CERO","cik":"0001870404","company_name":"CERO THERAPEUTICS HOLDINGS, INC.","filed_at":"2026-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.623132+00:00","generated_at":"2026-05-16T05:24:13.976830+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.95,"calibrated_materiality_score":0.95,"confidence":"high","headline":"Nasdaq Listing Council affirms delisting of CERo Therapeutics securities","bullets":["On Jan 29, 2026, the Nasdaq Listing and Hearing Review Council upheld the Panel's Oct 29, 2025 decision to delist CERo common stock and warrants.","Delisting and trading suspension originally effective Oct 31, 2025; the Council's affirmance makes the delisting final.","Common stock ticker CERO and warrants ticker CEROW will no longer trade on Nasdaq."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-011587","json":"https://secwatch.observer/filing/0001213900-26-011587.json","markdown":"https://secwatch.observer/filing/0001213900-26-011587.md","text":"https://secwatch.observer/filing/0001213900-26-011587.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/0001213900-26-011587-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/ea0274896-8k_cero.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:24:13.976830+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4491ff78ac9d73577ad20d8e9ab5e1b7c1ee2130","claim":"CERO THERAPEUTICS HOLDINGS, INC. received a nasdaq delisting notice notice regarding other.","evidence_excerpt":"January 29, 2026, after considering the written record in this matter, the Council issued its decision affirming the Panel’s decision to delist the Company’s securities from Nasdaq. 1 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 3, 2026 CERO THERAPEUTICS HOLDINGS, INC. By: /s/ Chris Ehrlich Name: Chris Ehrlich Title: Chief Executive Officer 2","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/0001213900-26-011587-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}